Coherus Oncology, Inc.
NASDAQ:CHRS · NASDAQ Global Market
+$0.03 today
Vol 1.26M · Avg 1.15M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-279.1%
avg 200.0%
ROIC
-151.8%
avg -103.3%
ROA
-65.9%
avg -63.3%
Analysis
ROA is currently the strongest return metric at -65.9% versus its period average of -63.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Dennis Lanfear | Chairman, President & Chief Executive Officer | $1.91M | — | 71 | $500,000.00 | 0.41% |
Sameer Goregaoker | Chief Commercial Officer | $854,058.00 | — | — | — | — |
Bryan J. McMichael | Chief Financial Officer | $788,885.00 | — | 47 | $30,000.00 | 0.02% |
Rosh Dias MRCP | Chief Medical Officer | — | — | 58 | — | — |
Arvind Sood | Chief Strategy & Corporate Affairs Officer | — | — | — | — | — |
Rebecca Sunshine | Chief Human Resources Officer | — | — | 63 | — | — |
Michael Chen | Senior Vice President of Commercial Analytics & Trade | — | — | — | $60,000.00 | 0.05% |
Carrie Graham | Vice President of Investor Relations & Advocacy | — | — | — | — | — |
Theresa Lavallee | Chief Development Officer & Chairman of Scientific Advisory Board | — | — | 60 | — | — |
Andy Rittenberg | Chief Legal Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +310.4% | +4.7% (14yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +310.4% over three years. Forward estimates point to Revenue at +4.7% (14yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
$1.18B
C4 Therapeutics, Inc.
NASDAQ:CCCC
$335.80M
OmniAb, Inc.
NASDAQ:OABI
$259.07M
Codexis, Inc.
NASDAQ:CDXS
$226.79M
Protalix BioTherapeutics, Inc.
AMEX:PLX
$169.60M
Avalo Therapeutics, Inc.
NASDAQ:AVTX
$169.58M
Protara Therapeutics, Inc.
NASDAQ:TARA
$155.32M
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
$143.87M
Invivyd, Inc.
NASDAQ:IVVD
$128.31M
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
$72.83M
Who manages CHRS?
Coherus Oncology, Inc. (CHRS) lists 10 active executives. The top listed executive is Rosh Dias MRCP, Chief Medical Officer.
Are CHRS insiders buying or selling?
Recent insider activity shows net selling of $29.84M.
Explore More
Continue the stock analysis
Jump to another research area for this company.